ArticleBlood advances2024
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03613532 (A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Who cites it
39 citing papers in PubMed, 36 citations in OpenAlex.
- Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.Bone marrow transplantation · 2026Article
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.Transplantation and cellular therapy · 2026Article
- Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.Annals of hematology · 2026Article
- Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study.Blood cancer journal · 2026Article
- Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes.Bone marrow transplantation · 2026Review
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Novel treatment strategies in acute myeloid leukemia.Blood research · 2026Review
- BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.Blood advances · 2026Article
- MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.Annals of hematology · 2026Observational
- Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.Blood advances · 2026Article
- Review
- Current and emerging maintenance strategies after stem cell transplantation in children and adolescents with acute leukemias.Molecular therapy. Oncology · 2026Review
- Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.Blood advances · 2026Article
- Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.Blood advances · 2026Article
- Transplant outcomes after intensive chemotherapy or venetoclax plus azacitidine in acute myeloid leukemia: a multicenter retrospective study in Japan.Clinical hematology international · 2026Article
- Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia.Frontiers in pharmacology · 2026Article
- Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report.Frontiers in immunology · 2026Article
- The tumor microenvironment in leukemia: molecular pathways of immune evasion.Frontiers in immunology · 2026Review
- AML, Myelodysplasia-Related: Beyond Classification-Toward Precision Decision-Making.Mediterranean journal of hematology and infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 2 countries.
Funding
Abstract
abstractWe conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) undergoing reduced intensity allogeneic stem cell transplantation (allo-SCT) after Ven and fludarabine/busulfan conditioning (Ven/FluBu2 allo-SCT) with tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis. Among 27 patients who underwent Ven/FluBu2 allo-SCT (55.6% with prior Ven exposure, and 96% with positive molecular measurable residual disease), 22 received maintenance therapy with Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 per assigned dose schedule/level (42-day cycles × 8, or 28-day cycles × 12). During maintenance, the most common grade 3-4 adverse events were leukopenia, neutropenia, and thrombocytopenia, which were transient and manageable. Infections were uncommon (n = 4, all grade 1-2). The 1-year and 2-year moderate/severe chronic GVHD rates were 4% (95% confidence interval [CI], 0.3%-18%) and 22% (95% CI, 9%-40%), respectively. After a median follow-up of 25 months among survivors, the median overall survival (OS) was not reached. Among the 22 patients who received Ven/Aza maintenance, the 2-year OS, progression-free survival, nonrelapse mortality, and cumulative incidence of relapse rates were 67% (95% CI, 43%-83%), 59% (95% CI, 36%-76%), 0%, and 41% (95% CI, 20%-61%), respectively. Immune monitoring demonstrated no significant impact on T-cell expansion but identified reduced B-cell expansion compared with controls. This study demonstrates prophylactic Ven/Aza maintenance can be safely administered for patients with high-risk MDS/AML, but a randomized study is required to properly assess any potential benefit. This trial was registered at www.clinicaltrials.gov as #NCT03613532.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.